XFOR ▲ +2.5% - X4 Pharmaceuticals, Inc.
$XFOR - X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
X4 Pharmaceuticals rose 2.5% following the company's announcement of a positive outcome from an FDA Type C meeting, which typically addresses important issues in drug development and regulatory pathways. A favorable meeting outcome suggests progress toward potential approval or advancement of the company's pipeline candidates, supporting investor optimism.
08-SEP-2026 07:01 AM ET
Share this post
More filings for $XFOR
XFOR - X4 Pharmaceuticals, Inc. - SEC Filing Update (21-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 22, 2026XFOR ▲ +2.9% - X4 Pharmaceuticals, Inc.Sep 9, 2026XFOR ▲ +0.5% - X4 Pharmaceuticals, Inc.Sep 1, 2026XFOR - X4 Pharmaceuticals, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026$XFOR SEC Filing Update (30-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 30, 2026
View full $XFOR filing history →💬 Comments
Loading comments…
Leave a comment
